What Science 37 Does

Science 37 is a pioneering provider of decentralized clinical trial (DCT) solutions. The company operates a proprietary technology platform, the Metasite®, that enables clinical research to be conducted remotely. This approach allows patients to participate from their homes or local clinics, reducing the burden of travel to traditional research sites. Science 37 provides the operational backbone, including telemedicine investigators, remote coordinators, mobile nurses, and connected devices, to manage trials end-to-end. By decentralizing trials, the company aims to accelerate enrollment, improve patient diversity and retention, and generate higher-quality, real-world data.

Why AI Matters at This Scale

For a growth-stage company like Science 37 with 501-1000 employees, AI is not a futuristic concept but a critical lever for scaling efficiency and solidifying its competitive edge. At this size, the company has moved beyond startup survival and is optimizing for profitability and market leadership. Manual processes in patient screening, data management, and site monitoring become significant cost centers and bottlenecks. AI automation allows Science 37 to handle a greater volume of trials and participants without linearly increasing its operational headcount. It transforms its platform from a facilitator of remote trials into an intelligent system that predicts issues, personalizes patient engagement, and unlocks insights from continuous data streams, directly impacting its value proposition to pharmaceutical sponsors.

Concrete AI Opportunities with ROI Framing

1. AI-Powered Patient Pre-Screening & Matching: Manually reviewing patient records against complex trial criteria is slow and error-prone. An NLP model can automate this, parsing EHRs and patient-reported data to identify eligible candidates in days instead of months. For a sponsor, reducing enrollment time by 30% can save over $1M per month in delayed market entry, creating a powerful ROI for Science 37's premium services.

2. Predictive Analytics for Patient Adherence & Site Performance: Patient dropout and underperforming sites cripple trial timelines and data integrity. Machine learning can analyze wearable device data, eCOA completion rates, and site historical performance to generate risk scores. Proactive interventions for high-risk participants or sites can improve retention by 15-20%, protecting millions in sunk trial costs and ensuring reliable data collection.

3. Automated Clinical Data Review & Query Management: Data managers spend countless hours reviewing case report forms for discrepancies. AI can be trained to flag potential anomalies, missing entries, and protocol deviations automatically. This reduces manual review time by up to 50%, allowing staff to focus on complex issues, accelerating database lock, and improving data quality—a key metric for sponsor satisfaction.

Deployment Risks Specific to This Size Band

At the 501-1000 employee scale, Science 37 faces specific AI deployment risks. Resource Allocation is a primary concern: the company must fund AI initiatives while maintaining core operations, risking overextension if projects lack clear, quick wins. Integration Complexity is heightened, as AI tools must connect seamlessly with its existing platform, sponsor systems, and various EMRs, requiring significant engineering effort. Regulatory Scrutiny is paramount; the FDA's focus on software as a medical device (SaMD) and data integrity means any AI tool must be fully validated, explainable, and audit-ready—a process requiring specialized expertise the company may need to acquire. Finally, Talent Acquisition for AI/ML roles is fiercely competitive, and a company of this size may struggle to attract top talent against larger tech and pharma giants, potentially slowing development cycles.